UKVIA raises concern over EU e-cigarette tax plan

Nov.30.2022
UKVIA raises concern over EU e-cigarette tax plan
The UK Vaping Industry Association expresses concerns over EU's e-cigarette tax plan, fearing negative impact on public health.

The UK Vaping Industry Association (UKVIA) has expressed concern about the European Commission's leaked plan to tax electronic cigarette products, citing worries that this could have a negative impact on public health. According to an article in the Financial Times, the plan aims to "bring the taxation of new smoking products, such as e-cigarettes and heated tobacco, into line with that of cigarettes.


Michael Landl, Director of the World Vaping Alliance, warns that imposing higher taxes on e-cigarette products will have a devastating impact on those attempting to quit smoking, and will likely result in a significant increase in the black market for e-cigarette products.


The committee claims that increasing taxes will improve public health, but in fact the opposite is true. For regular smokers trying to quit, lower-risk alternatives such as electronic cigarettes must be affordable. If the committee wants to alleviate the burden of smoking on public health, they must make e-cigarettes cheaper and more accessible, not less so.


The differing taxation of traditional cigarette and electronic cigarette products is essential for many people. Furthermore, high taxes on electronic cigarette products are particularly harmful to those in poor economic conditions because they are less likely to switch to electronic cigarettes, and this demographic represents the largest proportion of current smokers.


High taxes have the most impact on the most vulnerable groups. During times of multiple crises and people struggling to make ends meet, making e-cigarettes more expensive is the opposite of what we need. Policymakers must understand that taxing e-cigarettes will force people to resume smoking or turn to the black market, which is an undesirable situation. In times of crisis, people should not be subjected to unscientific and ideological anti-e-cigarette efforts. This needs to stop." Randall said.


The World Vapers’ Alliance has urged the European Union Commission and its member states to follow scientific evidence and avoid imposing higher taxes on e-cigarette products if they want to reduce the burden of smoking on public health. Availability and affordability of e-cigarette products must be ensured.


Instead of cracking down on e-cigarettes, the EU must ultimately accept reducing tobacco harm. What we need is risk-based regulation. The harm of e-cigarettes is 95% lower than smoking, so they cannot be treated the same way as traditional smoking," Landl added.


2FIRSTS will continue to provide coverage on this topic, with further updates available on the '2FIRSTS APP'. Scan the QR code below to download the app.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Group (Nasdaq: XXII) reported early commercial momentum for its FDA-authorized VLN® very low nicotine cigarettes, distributing approximately 8,800 cartons across 1,700 new U.S. retail outlets in the fourth quarter of 2025, while forecasting expansion to more than 5,000 retail points in 2026.
Business
Feb.24
Report: 43% of 546 Canadian specialty vape shops found non-compliant in federal inspections
Report: 43% of 546 Canadian specialty vape shops found non-compliant in federal inspections
Health Canada’s vaping compliance and enforcement report covering inspections from April 2024 to March 2025 found 43% of 546 specialty vaping businesses were not compliant with the Tobacco and Vaping Products Act and the Canada Consumer Product Safety Act, according to the report cited. Health inspectors seized vaping products at 235 specialty vaping establishments.
Feb.26 by 2FIRSTS.ai
Imperial Brands Forms Global AI Partnership with Capgemini, Reinforcing Artificial Intelligence as Core Infrastructure in the Nicotine Industry
Imperial Brands Forms Global AI Partnership with Capgemini, Reinforcing Artificial Intelligence as Core Infrastructure in the Nicotine Industry
Industry Insight
Feb.19
Alcohol, tobacco and cannabis use among Spanish students aged 14–18 hits historic lows
Alcohol, tobacco and cannabis use among Spanish students aged 14–18 hits historic lows
Spain’s 2025 Survey on Drug Use in Secondary Education (ESTUDES), presented by the Ministry of Health, reports historic lows in alcohol, tobacco and cannabis consumption among students aged 14 to 18. The survey shows past-30-day drinking fell from 56.6% in 2023 to 51% in 2025, tobacco use from 21.0% to 15.5%, and cannabis use from 15.5% to 11.6%.
Feb.09 by 2FIRSTS.ai
BAT’s Vuse Ultra listed as GOOD DESIGN Awards winner; features app connectivity and adjustable intensity
BAT’s Vuse Ultra listed as GOOD DESIGN Awards winner; features app connectivity and adjustable intensity
British American Tobacco’s (BAT) Vuse Ultra vaping product has been listed among winners on the U.S. GOOD DESIGN Awards website, in the “Personal Experience” category, according to the project page. The page identifies the award year as 2025 and names BAT (London) as both the entrant and the manufacturer.
Jan.20 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24